Tempus AI, Inc.
TEM
Hisse Senetlerindeki Sıralama
#1886
Tempus AI, Inc. operates as a healthcare technology company in the United... Tempus AI, Inc. operates as a healthcare technology company in the United States. It offers the Tempus platform, a closed-loop, full-stack, bi-directional integrations between a clinician's desktop and its laboratory diagnostic capabilities, analytics platform, and repository of multimodal data; and Hub, a clinical application for physicians and other healthcare providers for use in the diagnostics product line as an end-to-end application for healthcare providers for NGS tests. The company also provides Lens, a software application for life sciences and advanced precision research; diagnostics services, such as NGS diagnostics, PCR profiling, and other anatomic and molecular pathology tests; and large-panel solid tumor and hematologic testing through multiple assays, with its core clinical assay (xT and xR) offering large panel DNA, RNA full transcriptome, and incidental germline findings through normal blood or saliva analyses. In addition, it provides genetic tests focused on inherited conditions; an nP assay for pharmacogenomic testing for patients with psychiatric conditions, including depression, general anxiety disorder, bipolar disorder, and other relevant diagnoses; Insights, which licenses libraries of linked, de-identified clinical, molecular, and imaging data; Organoids, a tumor derived biological modeling. Further, the company offers Trials for clinical trial matching services; Next, an AI platform; Algos, an algorithm-based diagnostics application. It has Strategic Collaborations with AstraZeneca AB, Pathos AI, Inc., GlaxoSmithKline, Merck, and Recursion Pharmaceuticals, Inc. Additionally, it also has a strategic collaboration with Blood Cancer United to develop registry for pediatric acute myeloid leukemia. The company was formerly known as Tempus Labs, Inc. and changed its name to Tempus AI, Inc. in January 2023. Tempus AI, Inc. was incorporated in 2015 and is headquartered in Chicago, Illinois.
Hisse Fiyatı
$64.29
Son senkronizasyon: 2026-10-16
Piyasa Değeri
$11.28B
Değişim (1 gün)
-9.62%
Değişim (1 yıl)
-26.76%
Ülke
US
Ticaret Tempus AI, Inc. (TEM)
Kategori
Healthcare
Tempus AI, Inc. (TEM) için Faaliyet Marjı
October 2026 itibarıyla Faaliyet Marjı TTM: -19.76%
Tempus AI, Inc. şirketinin en son finansal raporlarına ve hisse fiyatına göre, mevcut faaliyet marjı (TTM) -19.76%'dir. 2023 yılı sonunda şirketin faaliyet marjı -36.87% idi.
Tempus AI, Inc. için 2019 ile 2026 arasındaki Faaliyet Marjı geçmişi
Her yıl sonunda Faaliyet Marjı
| Yıl | Faaliyet Marjı | Değiştir |
|---|---|---|
| 2026 (TTM) | -19.76% | -80.17% |
| 2024 | -99.67% | 170.33% |
| 2023 | -36.87% | -55.46% |
| 2022 | -82.78% | -12.42% |
| 2021 | -94.52% | -8.14% |
| 2020 | -102.90% | -46.69% |
| 2019 | -193.02% | 0.00% |
Benzer şirketler veya rakipler için Faaliyet Marjı
| Şirket | Faaliyet Marjı | Faaliyet Marjı Farkı | Ülke |
|---|---|---|---|
| 12.70% | -100.64% |
US
|
|
| 74.94% | -103.79% |
AU
|
|
| 3.33% | -100.17% |
US
|
|
| -14.33% | -99.27% |
US
|
|
| 0.00% | - |
US
|
Bir şirketin Faaliyet Marjı'ı nedir?
Faaliyet Marjı, bir şirketin kârlılığını değerlendirmek için temel bir göstergedir. Daha yüksek Faaliyet Marjı değerleri genellikle daha iyidir çünkü bir şirketin ürün veya hizmetlerini üretim maliyetlerinden çok daha yüksek bir fiyata satabildiğini gösterir. Faaliyet Marjı, şirketin kârının gelirine bölünmesiyle hesaplanır.